<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586170</url>
  </required_header>
  <id_info>
    <org_study_id>CS-027</org_study_id>
    <nct_id>NCT00586170</nct_id>
  </id_info>
  <brief_title>A Double-Blind Study on Adjunctive Use of PEMF in the Treatment of 5th Metatarsal Non-Union Fractures</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind Study on Adjunctive Use of Pulsed Electromagnetic Fields in the Treatment of 5th Metatarsal Non-Union Fractures: Effect on Clinical Outcome and Growth Factor Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the effect of PEMF in surgical reconstruction of 5th
      metatarsal non-union fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize:

        1. That treatment of 5th metatarsal non-union fracture with PEMF will achieve earlier
           resolution and/or higher success compared to surgery alone of 5th metatarsal non-union
           fractures.

        2. PEMF will stimulate increased expression of critical growth factors (i.e. BMP-2, BMP-4,
           BMP-7 as well as TGFb, IGF-1, FGF-2 and VEGF) at the non-union site to facilitate
           osseous healing of 5th metatarsal non-union fractures.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Successful 5th Metatarsal Unions Achieved.</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Each patient was assessed radiographically at 2, 4, 6, 8, 12, 16, 20, and 24 weeks or until radiographic signs of healing were evident. The radiographs were evaluated and graded by the number of cortices (medial and lateral on anteroposterior views as well as dorsal and plantar on lateral views) of healing at each time point. Bridging callus across 4 cortices on postoperative radiographs was used to determine healing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean AOFAS Score (% Change From Baseline), Foot Function Index (% Change From Baseline), SF-36 Health Survey (Change From Baseline)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Nonunion of Fracture of Fifth Metatarsal</condition>
  <arm_group>
    <arm_group_label>EBI Bone Healing System + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Device + Surgery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EBI Bone Healing System</intervention_name>
    <description>10 hours of treatment per day for up to 24 weeks</description>
    <arm_group_label>EBI Bone Healing System + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Device</intervention_name>
    <description>10 hours of treatment per day for up to 24 weeks</description>
    <arm_group_label>Placebo Device + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Open Reduction and Internal Fixation of the nonunion site</description>
    <arm_group_label>EBI Bone Healing System + Surgery</arm_group_label>
    <arm_group_label>Placebo Device + Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has been diagnosed with a 5th metatarsal delayed or non-union.

          2. Subjects with duration of a 5th metatarsal fracture for a minimum of 3 months.

          3. Male or female between ages of 18 and 75 years old, inclusive

        Exclusion Criteria:

          1. Subject has synovial pseudarthrosis.

          2. Subject has a fracture gap of larger than 5mm as measured on CT Scan.

          3. Subjects with conditions associated with elevated circulatory levels of inflammatory
             cytokines e.g., multiple trauma.

          4. If female, subject is pregnant, plans on becoming pregnant during the duration of this
             clinical outcomes collection study or lactating.

          5. Subject has an implanted unipolar pacemaker.

          6. Subjects who have previous malignant or connective tissue disorder.

          7. Subjects who use medication such as steroids or anticoagulants.

          8. Subjects who have an underlying osseous infection (Osteomyelitis) and/or open wound.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Evangelista</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurological Institute of NJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthopedic Foot and Ankle Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <results_first_submitted>March 9, 2016</results_first_submitted>
  <results_first_submitted_qc>April 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nonunion</keyword>
  <keyword>fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EBI Bone Healing System + Surgery</title>
          <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
EBI Bone Healing System: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
        <group group_id="P2">
          <title>Placebo Device + Surgery</title>
          <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
Placebo Device: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3">Initially enrollment was listed as 9. 1 placebo patient withdrew prior to surgery, so enrollment=8.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EBI Bone Healing System + Surgery</title>
          <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
EBI Bone Healing System: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
        <group group_id="B2">
          <title>Placebo Device + Surgery</title>
          <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
Placebo Device: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Successful 5th Metatarsal Unions Achieved.</title>
        <description>Each patient was assessed radiographically at 2, 4, 6, 8, 12, 16, 20, and 24 weeks or until radiographic signs of healing were evident. The radiographs were evaluated and graded by the number of cortices (medial and lateral on anteroposterior views as well as dorsal and plantar on lateral views) of healing at each time point. Bridging callus across 4 cortices on postoperative radiographs was used to determine healing.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Each patient had 1 fracture. The number of fractures treated equals the number of patients treated in both treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>EBI Bone Healing System + Surgery</title>
            <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
EBI Bone Healing System: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
          </group>
          <group group_id="O2">
            <title>Placebo Device + Surgery</title>
            <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
Placebo Device: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Successful 5th Metatarsal Unions Achieved.</title>
          <description>Each patient was assessed radiographically at 2, 4, 6, 8, 12, 16, 20, and 24 weeks or until radiographic signs of healing were evident. The radiographs were evaluated and graded by the number of cortices (medial and lateral on anteroposterior views as well as dorsal and plantar on lateral views) of healing at each time point. Bridging callus across 4 cortices on postoperative radiographs was used to determine healing.</description>
          <population>Each patient had 1 fracture. The number of fractures treated equals the number of patients treated in both treatment groups.</population>
          <units>percentage of fractures healed</units>
          <param>Number</param>
          <units_analyzed>Fractures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Fractures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AOFAS Score (% Change From Baseline), Foot Function Index (% Change From Baseline), SF-36 Health Survey (Change From Baseline)</title>
        <time_frame>24 Weeks</time_frame>
        <population>No AOFAS, Foot Function Index, or SF-36 Health Survey data was collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>EBI Bone Healing System + Surgery</title>
            <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
EBI Bone Healing System: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
          </group>
          <group group_id="O2">
            <title>Placebo Device + Surgery</title>
            <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
Placebo Device: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AOFAS Score (% Change From Baseline), Foot Function Index (% Change From Baseline), SF-36 Health Survey (Change From Baseline)</title>
          <population>No AOFAS, Foot Function Index, or SF-36 Health Survey data was collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire study period. Patients were followed through healing, or up to 24 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EBI Bone Healing System + Surgery</title>
          <description>Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
EBI Bone Healing System: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
        <group group_id="E2">
          <title>Placebo Device + Surgery</title>
          <description>Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
Placebo Device: 10 hours of treatment per day for up to 24 weeks
Surgery: Open Reduction and Internal Fixation of the nonunion site</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>unrelated complication - hernia</sub_title>
                <description>patient had vomiting and hernia obstruction 6 weeks post-surgery; had hernia surgery and recovered</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>unrelated complication - allergic reaction</sub_title>
                <description>patient had sick stomach on surgery day, 3 days later reported allergic reaction - increased swelling of the face, hands and legs. Discontinued medication and swelling discontinued. Vomiting and diarrhea reported 3 wks post-surgery. patient recovered</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Unrelated complication - leg bruising, breast lump</sub_title>
                <description>2 months post surgery patient had a lump in left breast and severe bruising on right leg. Could not be associated with device use.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Unrelated complication - anxiety</sub_title>
                <description>increased anxiety due to cast reported 3 weeks post-surgery. Patient recovered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager of Research</name_or_title>
      <organization>Biomet</organization>
      <phone>973-299-9300 ext 3415</phone>
      <email>hallie.murray@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

